Key result
A 5-day course of venoarterial extracorporeal membrane oxygenation successfully bridged a 41-year-old female with B-cell lymphoma and cardiogenic shock through her chemotherapy to hospital discharge.
Why the study?
Does venoarterial ECMO provide effective hemodynamic support as a bridge through chemotherapy in a patient with cardiogenic shock secondary to a mediastinal mass?
Case Report (n=1)
No
Does venoarterial ECMO provide effective hemodynamic support as a bridge through chemotherapy in a patient with cardiogenic shock secondary to a mediastinal mass?
Venoarterial ECMO can be successfully used as a temporary bridge to support hemodynamics in patients developing cardiogenic shock during chemotherapy for large mediastinal tumors.
Supports feasibility of short-term VA-ECMO bridging in chemotherapy-related cardiogenic shock; leaves open need for prospective validation.
A 41-year-old female presented with a large anterior mediastinal mass adjacent to the heart. Biopsy demonstrated lymphoma. Upon administration of chemotherapy, she developed cardiogenic shock requiring a 5-day course of extracorporeal membrane oxygenation (ECMO) as a bridge through her treatment. After one cycle of chemotherapy, ECMO was discontinued and the patient completed her course of chemotherapy and recovered to hospital discharge.
No takes yet. Share an insight, caveat, or question.
Worku et al. (2015) conducted a case report in B-Cell Lymphoma with cardiogenic shock (n=1). Extracorporeal membrane oxygenation (ECMO) was evaluated on Recovery to hospital discharge. A 5-day course of venoarterial extracorporeal membrane oxygenation successfully bridged a 41-year-old female with B-cell lymphoma and cardiogenic shock through her chemotherapy to hospital discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: